Anfibatide

安菲博肽

Report date: 2024/12/05 16:30:16

Base Information

Drug NameAnfibatide
Drug Alias NameAntiplatelet thrombolysin for injection - Lee's PharmaceuticalDeclotanaZK-001
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlycoprotein Ib platelet alfa subunit antagonists
TargetsGlycoprotein Ib platelet alfa subunit
Therapy Area/IndicationsAcquired thrombotic thrombocytopenic purpuraBlood Coagulation DisordersST Elevation Myocardial Infarction +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesLee'S Pharmaceutical (Hk) Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZhaoke Pharmaceutical (Hefei) Co Ltd
Inactive CompaniesLee'S Pharmaceutical LtdZhaoke Pharmaceutical (Hefei) Co Ltd Guangzhou Branch
Active IndicationsStroke
Inactive IndicationsAcquired thrombotic thrombocytopenic purpuraBlood Coagulation DisordersST Elevation Myocardial Infarction +[6] 

Other Information

ATC CodeB01AC
Related LinksDrugBank